logo
Plus   Neg
Share
Email

Celgene Finalises Acquisition Of Juno Therapeutics

Celgene Corp. (CELG) Tuesday said it completed the acquisition of Juno Therapeutics, Inc. The shares of Juno will no longer be trading on the NASDAQ.

Celgene offered $9 billion or $87 per share for the Seattle-based Juno Therapeutics.

Celgene said it would also gain full global rights to JCAR017 and expects the addition of JCAR017 and other cellular immunotherapy products to accelerate revenue diversification with meaningful growth drivers from 2020 and beyond.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
California's insurance regulator has filed a lawsuit against AbbVie Inc. for allegedly giving illegal kickbacks to health care providers to prescribe its arthritis drug Humira. The lawsuit filed in Alameda County Superior Court by the California Department of Insurance alleges that private insurers have paid out $1.2 billion in Humira-related pharmacy claims. Danske Bank A/S's Chief Executive Thomas Borgen resigned on Wednesday after the Danish lender announced the results of an internal probe relating to a money-laundering scandal in its branch in Estonia that involved payments of about 200 billion euros. Danske Bank said its investigation covered about 15,000 customers and a total of around 9.5 million payments through the branch. The Competition and Markets Authority (CMA) in the United Kingdom confirmed Wednesday that the proposed merger between J Sainsbury plc (JSAIY.PK, SBRY.L) and Asda Group Ltd. is being referred for an in-depth Phase 2 investigation. CMA noted that the deal raises sufficient concerns through its Phase...
Follow RTT